Phase II Study of Pertuzumab, Trastuzumab and Weekly Paclitaxel in HER2-Overexpressing Metastatic Breast Cancer


Phase II Study of Pertuzumab, Trastuzumab and Weekly Paclitaxel in HER2-Overexpressing Metastatic Breast Cancer
Slides from a presentation at SABCS 2012 and transcribed comments from a recent interview with Edith A Perez, MD (1/17/13)
Datko F et al. Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer. San Antonio Breast Cancer Symposium 2012;Abstract P5-18-20.

Dr Perez is Deputy Director at Large of the Mayo Clinic Cancer Center, Group Vice Chair of the Alliance of Clinical Trials in Oncology and Serene M and Frances C Durling Professor of Medicine at the Mayo Clinic in Jacksonville, Florida.